semaglutide and cardiovascular disease Insights into research: Mechanisms, trials, frontiers VisualAbstract: Semaglutide in Patients with

Cardiovascular Support (Off-label): Adjunctive therapy in certain cardiomyopathies where fatty acid metabolism is impaired

4 r 4.9% ARR reported at 3 years in prespecified supplementary analysis

Ideal candidates typically have a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related health condition such as high blood pressure, pre-diabetes, or sleep apnea

Inflammation can irritate blood vessels and may contribute to plaque buildup, clotting problems, and vascular stress

Hormone Regulation The gut microbiome influences the regulation of various hormones in the body, including those produced by the thyroid gland